Salicylates are the group of chemicals that has salicylic acid as the parent compound and have the ability to treat inflammation, pain syndromes, brain and cardiovascular disorders. The present study was designed to investigate the protective effect of loaded sodium salicylates on nanoparticles to treat brain toxicity induced by cisplatin and decrease the drug side effects. Cisplatin 02 mg/kg BW was given alone or in combination with sodium salicylate loaded on nanoparticles (Si-Sc-NPs) [100 mg/kg BW] for three weeks. The obtained results indicate that Si-Sc-NPs decrease oxidative stress markers such as malondialdehyde (MDA), nitric oxide (NO), and paraoxonase-1 (PON-1) activity in brain. There were also decreased in Monocyte Chemo-attractant Protein-1 (MCP-1) activities and Nuclear Factor kappa β (NF-kβ) level of brain tissue while the Butyrylcholinesterase (BChE) activities of brain tissue increased after Si-Sc-NPs treatment. Histopathological results showed that cisplatin group showed several neurodegenerative changes, on the other hand, group treated with Si-Sc-NPs +Cis showed improvement in almost brain structure and mild pyknotic nuclei and apoptotic neurons were observed.

Background Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs expression (up or down regulation) can affect the initiation and progression of many malignancies. We aimed to evaluate the role of circulating miRNA-148a and miRNA-30c in female patients with breast cancer and estimate their usage as potential biomarkers in the diagnosis, prognosis and survival of breast cancer. Methods This study included 75 breast cancer female patients.They were compared with 55 apparently healthy female subjects. miRNAs expression analysis was assessed via real-time PCR. Results To discriminate breast cancer patients from controls, miR-30c showed the best performance at a cut off value of ≤20.6 (AUC = 0.998, 97.33% sensitivity, 96.36% specificity, p < 0.001), followed by miR-148a (AUC = 0.995, 94.67% sensitivity, 90.91% specificity, p < 0.001 at a cut off value of ≤0.1), CA 15-3 (AUC = 0.930, 88.0% sensitivity, 81.82% specificity, p < 0.001 at a cut off value of >21.3), and finally CEA (AUC = 0.751, 70.67% sensitivity, 63.64% specificity, p < 0.001 at a cut off value of >2.5). Conclusion miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer and might be considered as potential blood biomarkers. Both also might have rule in disease treatment and selection of therapeutic targets. Future studies are needed to improve their role in predicting response to treatment and prognosis.

No abstract

No abstract

No abstract